VRTX
Vertex Pharmaceuticals Incorpor · Healthcare · Biotechnology
TECHSellZACKSHold
R500#357 today
$504.73
-0.40% today · -4.08% 1W
Oct 2 close or latest
PreviewWhy it's moving
Underperforming without a clear catalyst yet
- VRTX −0.40% on the last session vs SPY +0.74%: −1.1 pts of stock-specific move.
- Aftermath, big drop (Oct 1): After its 61 big drops in the past 5 years, VRTX typically gained 0.5% over the next day (median) and was higher 62% of the time; half the outcomes fell between -0.9% and +1.5%. An ordinary day: +0.1%. Among S&P 500 stocks after big drops, that ranks #13 of 500.
- Market backdrop (Fri): Average Hourly Earnings m/m 0.1% vs 0.3% expected (cooler); Non-Farm Employment Change 29K vs 89K expected (weaker); S&P futures +0.41%, 10-year yield -5bp in the 30 minutes after.
Assembled from Wallsti's own signals.
Key facts
- Market cap
- $127.9B
- Held by institutions
- 97.9%
- Short interest
- 2.1%
- 52-week range
- 400.74–560.25
- Analyst mean target
- —
- Next earnings
- Nov 2
- Forward P/E
- 25.1
Recent events
Earnings ▼
2Q2026 results: EPS $4.73 vs $4.75 expected miss −$0.02 (−0.3%); revenue $3.3B; next session +1.7% (-0.1 vs SPY)Earnings ▲
1Q2026 results: EPS $4.47 vs $4.31 expected beat +$0.16 (+3.8%); revenue $3.0B; next session -1.3% (-2.1 vs SPY)Earnings ▼
4Q2025 results: EPS $5.03 vs $5.15 expected miss −$0.12 (−2.3%); revenue $3.2B; next session +5.7% (+5.6 vs SPY)Earnings ▲
3Q2025 results: EPS $4.80 vs $4.58 expected beat +$0.22 (+4.9%); revenue $3.1B; next session -1.0% (+0.2 vs SPY)